AMERIPRISE FINANCIAL INC — 13F Holdings & Portfolio

CIK 820027 · latest 13F-HR filed 2026-07-17

AMERIPRISE FINANCIAL INC manages $2.5M in 13F-reported U.S. long-equity assets across 2 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are ZURA (67.91%), MIST (32.09%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 2 new positions, exited 4,012, added to 0, and trimmed 0.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Filer Information
Address
1099 AMERIPRISE FINANCIAL CENTER
MINNEAPOLIS, MN 55474
Phone
(612) 671-8001
Filing Manager
AMERIPRISE FINANCIAL INC
MINNEAPOLIS, MN
Signatory
Michael G. Clarke
Senior VP, NA Head of Operations & Investor Services
Loading holdings…
AUM

$2.5M

Long-equity book

Holdings

2

Distinct positions

Period

2026-03-31

Filed 2026-07-17

Q/Q Activity

+2 / −4012 / ↑0 / ↓0

vs 2026-03-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • No increased positions.
Show all 0

Top Trims

  • No decreased positions.
Show all 0

New Positions

  • Zura Bio Limited$1.7M
  • Milestone Pharmaceuticals Inc$793.3K
Show all 2

Exited Positions

  • NVIDIA CORP$16.06B
  • APPLE INC$11.78B
  • MICROSOFT CORP$11.50B
  • ALPHABET INC-CL A$9.50B
  • BROADCOM INC$8.17B
Show all 4012
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 Zura Bio Limited ZURA G9TY5A101 $1.7M 67.91% 282,207 SH
2 Milestone Pharmaceuticals Inc MIST 59935V107 $793.3K 32.09% 666,666 SH
Filing History
Period Filed AUM Holdings Accession
2026-03-31 2026-05-15 $431.76B 11,197 0001193125-26-225866
2026-03-31 2026-07-17 $2.5M 2 0001193125-26-307058
2026-03-31 2026-07-17 $431.78B 11,197 0001193125-26-307051
2025-12-31 2026-02-17 $442.51B 11,224 0001193125-26-053888
2025-09-30 2025-11-14 $435.39B 11,107 0001193125-25-282109